Postdoctoral Research Station of Medicine, School of Medicine, Tongji University, Shanghai, China.
Department of Clinic Medicine, Anhui Medical University, Hefei, China.
Biomed Pharmacother. 2018 Jan;97:293-299. doi: 10.1016/j.biopha.2017.10.078. Epub 2017 Nov 6.
To assess the effects of laser photocoagulation as monotherapy or adjuvant therapy for the treatment of DME.
A search of the Cochrane Library, Pubmed, Embase, and the clinicaltrial.gov registry for randomized clinical trials comparing any two treatments of interest (SDMLP monotherapy, CLP monotherapy, CLP plus anti-VEGF therapy) was performed. Data were collected and pooled by Bayesian network meta-analyses which accounts for both direct and indirect comparisons. The primary outcome was the mean change in best-corrected visual acuity measured by the logarithm of the minimal angle of resolution units. The secondary outcome was the mean change in central macular thickness from baseline to month 12.
Ranibizumab therapy combined with CLP was more effective than SDMLP alone (MD, -0.396; 95% CrI, -0.746 to -0.062) and CLP alone (MD, -0.621; 95% CrI, -0.823 to -0.431). There was no apparent difference of efficacy between SDMLP alone and CLP alone (MD, -0.225; 95% CrI, -0.501 to 0.058). There was no apparent difference of efficacy between SDMLP alone and Bevacizumab therapy combined with CLP (MD, -0.003, 95% CrI, -0.815 to 0.805).
There was no apparent difference on improving vision between SDMLP monotherapy and CLP monotherapy. The most effective treatment in the network was ranibizumab therapy combined with CLP followed by SDMLP monotherapy, Bevacizumab therapy combined with CLP, and CLP monotherapy in rank order.
评估激光光凝作为单一疗法或辅助疗法治疗 DME 的效果。
对 Cochrane 图书馆、Pubmed、Embase 和 clinicaltrial.gov 注册中心进行了检索,以查找比较任何两种治疗方法(SDMLP 单一疗法、CLP 单一疗法、CLP 联合抗 VEGF 治疗)的随机临床试验。通过贝叶斯网络荟萃分析收集和汇总数据,该分析同时考虑了直接和间接比较。主要结局是通过最小角分辨率单位对数测量的最佳矫正视力的平均变化。次要结局是从基线到第 12 个月中央黄斑厚度的平均变化。
雷珠单抗联合 CLP 治疗比 SDMLP 单一疗法(MD,-0.396;95% CrI,-0.746 至-0.062)和 CLP 单一疗法(MD,-0.621;95% CrI,-0.823 至-0.431)更有效。SDMLP 单一疗法和 CLP 单一疗法的疗效差异不明显(MD,-0.225;95% CrI,-0.501 至 0.058)。SDMLP 单一疗法和贝伐单抗联合 CLP 治疗的疗效差异也不明显(MD,-0.003,95% CrI,-0.815 至 0.805)。
SDMLP 单一疗法和 CLP 单一疗法在改善视力方面没有明显差异。网络中最有效的治疗方法是雷珠单抗联合 CLP 治疗,其次是 SDMLP 单一疗法、贝伐单抗联合 CLP 治疗和 CLP 单一疗法。